We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Biomarker Associated with Risk of Alzheimer Disease

By LabMedica International staff writers
Posted on 21 Apr 2011
Increased levels in the blood of a specific biomarker are significantly associated with the prevalence and severity of Alzheimer disease (AD), but not with the risk of onset of new disease.

The protein clusterin, also known as apolipoprotein J, have been found to be increased in brain and cerebrospinal fluid of patients with AD, and have been suggested to be involved in the pathogenesis of AD. More...


Scientists at Erasmus University Medical Center (Rotterdam, The Netherlands) analyzed the plasma levels of clusterin measured at baseline from 1997 to 1999, in 60 individuals with prevalent AD, a random subgroup of 926 participants, and an additional 156 participants diagnosed with AD during the average 7.2 years of follow-up, until January 2007. Clusterin levels were analyzed via multiplex immunoassay on a human multianalyte profile at the Rules-Based Medicine's multiplexed biomarker testing laboratory, (Austin, TX, USA). The lowest detectable level was 1.3 μg/mL. The intra-assay variability was less than 4% and the interassay variability was less than 13%.

The scientists found that the likelihood of prevalent AD increased with increasing plasma levels of clusterin, with the odds increased by 63% for every standard deviation increase in clusterin levels, after adjusting for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension. Among patients with AD, higher clusterin levels were associated with more severe disease. There was no statistically significant association of plasma clusterin levels with new AD during total follow-up or with new AD within or after three years of baseline. The results for all-cause dementia and vascular dementia were similar.

The authors of study concluded that the data from the general population show that increased plasma-clusterin levels are associated with prevalent AD and are higher in more severe cases of AD. However, increased levels of clusterin do not precede development of AD and therefore are not a potential early marker of subclinical disease. The study was published in the April 2011 edition of the Journal of the American Medical Association (JAMA).

Related Links:
Erasmus University Medical Center
Rules-Based Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.